Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Roche Holding AG
  6. News
  7. Summary
    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Roche : Invitation to Roche's Virtual Pharma Day - Tuesday, 14th September 2021

07/30/2021 | 08:09am EDT
Investor Update Invitation to Roche's Virtual Pharma Day - Tuesday, 14th September 2021


The Roche Investor Relations team would like to invite you to Roche's Virtual Pharma Day 2021 that will take place as a live webinar on

Tuesday, 14th September 2021
14:00 - 17:00 CEST / 13:00 - 16:00 BST
8:00 - 11:00 am EDT / 5:00 - 8:00 am PDT

The webinar will start with presentations, followed by a Q&A session.

  • Pharma strategy, Culture and organization, New technologies
  • Market opportunities, Launches, Commercial model & Access
  • Late stage pipeline: Oncology, Neuroscience, Immunology, Ophthalmology, Infectious diseases

Presenters:

  • Bill Anderson, Chief Executive Officer Roche Pharmaceuticals
  • Teresa Graham, Head of Pharma Global Product Strategy
  • Levi Garraway, Chief Medical Officer and Head Global Product Development
  • Paulo Fontoura, Global Head of Neuroscience, Immunology, Ophthalmology, Infectious and Rare Diseases, Clinical Development
  • Nilesh Mehta, Life Cycle Leader Faricimab
  • Barry Clinch, Global HeadInfectious Diseases, Clinical Development


We would like to invite all interested parties to participate in the webinar and to pre-register here.*
Should you be unable to register for the webinar due to your company IT policy, please send an email to investor.relations@roche.com.

A replay of the event will be available via > ir.roche.com

*privacy notice

Best regards,

Karl Mahler
Head of Investor Relations


Bruno Eschli
Investor Relations Officer
Roche Investor Relations
Dr. Karl Mahler
Phone: +41 61 68-78503
e-mail: karl.mahler@roche.com
Jon Kaspar Bayard
Phone: +41 61 68-83894
e-mail: jon_kaspar.bayard@roche.com
Dr. Sabine Borngräber
Phone: +41 61 68-88027
e-mail: sabine.borngraeber@roche.com
Dr. Bruno Eschli
Phone: +41 61 68-75284
e-mail: bruno.eschli@roche.com
Dr. Birgit Masjost
Phone: +41 61 68-84814
e-mail: birgit.masjost@roche.com
Dr. Gerard Tobin
Phone: +41 61 68-72942
e-mail: gerard.tobin@roche.com
Investor Relations North America
Loren Kalm
Phone: +1 650 225 3217
e-mail: kalm.loren@gene.com

Disclaimer

Roche Holding AG published this content on 30 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 July 2021 12:08:18 UTC.


ę Publicnow 2021
All news about ROCHE HOLDING AG
01:44aROCHE : Muscular Disease Therapies Show Efficacy In Various Studies
MT
01:00aPRESS RELEASE : Roche presents new data at World -2-
DJ
01:00aPRESS RELEASE : Roche presents new data at World Muscle Society (WMS) 2021 highlighting ne..
DJ
01:00aROCHE : presents new data at World Muscle Society (WMS) 2021 highlighting new advances for..
AQ
09/23ROCHE : WHO Recommends Roche-Regeneron COVID-19 Antibody Cocktail For High-Risk Patients
MT
09/23REGENERON PHARMACEUTICALS : WHO backs Regeneron COVID-19 drug cocktail as UN body calls fo..
RE
09/23ROCHE HOLDINGS AG : Credit Suisse gives a Neutral rating
MD
09/23ROCHE : Canadian Blood Services selects Roche Diagnostics Canada as a partner of choice fo..
AQ
09/22ROCHE : Joins CG Oncology to Study Novel Immunotherapy Combination in Cancer Patients
MT
09/22ROCHE : Rolls Out Three Respiratory Tests On Cobas 6800/8800 Systems
MT
More news
Analyst Recommendations on ROCHE HOLDING AG
More recommendations
Financials
Sales 2021 61 371 M 66 361 M 66 361 M
Net income 2021 14 747 M 15 945 M 15 945 M
Net cash 2021 4 289 M 4 637 M 4 637 M
P/E ratio 2021 19,8x
Yield 2021 2,76%
Capitalization 298 B 322 B 322 B
EV / Sales 2021 4,78x
EV / Sales 2022 4,61x
Nbr of Employees 101 465
Free-Float 83,5%
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 340,40 CHF
Average target price 382,65 CHF
Spread / Average Target 12,4%
EPS Revisions
Managers and Directors
Severin Schwan Chief Executive Officer & Executive Director
Alan Hippe Chief Financial & Information Technology Officer
Christoph Franz Chairman
Urs Jaisli Chief Compliance Officer
AndrÚ S. Hoffmann Vice Chairman
Sector and Competitors
1st jan.Capi. (M$)
ROCHE HOLDING AG10.87%324 441
JOHNSON & JOHNSON4.75%433 991
PFIZER, INC.19.40%247 760
NOVO NORDISK A/S51.58%233 750
ELI LILLY AND COMPANY37.51%210 490
ABBVIE INC.0.20%189 724